Previous close | 12.35 |
Open | 12.35 |
Bid | 11.60 |
Ask | 13.40 |
Strike | 39.00 |
Expiry date | 2024-07-19 |
Day's range | 12.35 - 12.35 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NY
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck’s blockbuster immunotherapy, Keytruda. Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer With encouraging results, Pfizer is getting another step closer t
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.